MA54958A - Modulation de l'activité de la protéine rep dans la production d'adn à extrémité fermée - Google Patents
Modulation de l'activité de la protéine rep dans la production d'adn à extrémité ferméeInfo
- Publication number
- MA54958A MA54958A MA054958A MA54958A MA54958A MA 54958 A MA54958 A MA 54958A MA 054958 A MA054958 A MA 054958A MA 54958 A MA54958 A MA 54958A MA 54958 A MA54958 A MA 54958A
- Authority
- MA
- Morocco
- Prior art keywords
- modulation
- closed
- protein activity
- rep protein
- end dna
- Prior art date
Links
- 230000004952 protein activity Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
- C12N2810/6018—Adenoviridae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2820/00—Vectors comprising a special origin of replication system
- C12N2820/002—Vectors comprising a special origin of replication system inducible or controllable
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2820/00—Vectors comprising a special origin of replication system
- C12N2820/60—Vectors comprising a special origin of replication system from viruses
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962806076P | 2019-02-15 | 2019-02-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA54958A true MA54958A (fr) | 2021-12-22 |
Family
ID=72045641
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA054958A MA54958A (fr) | 2019-02-15 | 2020-02-14 | Modulation de l'activité de la protéine rep dans la production d'adn à extrémité fermée |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220127625A1 (https=) |
| EP (1) | EP3924491A4 (https=) |
| JP (2) | JP7644014B2 (https=) |
| KR (1) | KR20210127935A (https=) |
| CN (1) | CN113454232B (https=) |
| AU (1) | AU2020221312A1 (https=) |
| CA (1) | CA3129321A1 (https=) |
| IL (1) | IL285415A (https=) |
| MA (1) | MA54958A (https=) |
| SG (1) | SG11202106491VA (https=) |
| WO (1) | WO2020168222A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ762100A (en) | 2017-08-09 | 2025-12-19 | Bioverativ Therapeutics Inc | Nucleic acid molecules and uses thereof |
| EP3833766A1 (en) | 2018-08-09 | 2021-06-16 | Bioverativ Therapeutics Inc. | Nucleic acid molecules and uses thereof for non-viral gene therapy |
| WO2020251954A1 (en) * | 2019-06-10 | 2020-12-17 | Homology Medicines, Inc. | Adeno-associated virus compositions for arsa gene transfer and methods of use thereof |
| JP2023535632A (ja) | 2020-07-27 | 2023-08-18 | アンジャリウム バイオサイエンシズ エージー | Ｄｎａ分子の組成物、その作製方法、及びその使用方法 |
| EP4214309A4 (en) * | 2020-09-16 | 2025-07-16 | Generation Bio Co | CLOSED-END DNA VECTORS AND RELATED USES FOR EXPRESSING PHENYLALANINE HYDROXYLASE (PAH) |
| WO2022136616A1 (en) * | 2020-12-23 | 2022-06-30 | Vivet Therapeutics | Minimal bile acid inducible promoters for gene therapy |
| EP4308705A4 (en) * | 2021-03-16 | 2025-06-04 | Wisconsin Alumni Research Foundation | INSULIN GENE THERAPY TO TREAT DIABETES |
| MX2024002333A (es) * | 2021-08-23 | 2024-03-07 | Bioverativ Therapeutics Inc | Sistema de expresion de baculovirus. |
| CN114703203B (zh) * | 2022-02-11 | 2024-08-06 | 上海渤因生物科技有限公司 | 杆状病毒载体及其用途 |
| KR102737146B1 (ko) * | 2023-07-10 | 2024-12-09 | 대한민국 | 신규 발현 벡터 및 이의 용도 |
| WO2025114932A1 (en) * | 2023-11-30 | 2025-06-05 | Sanofi | Purification of closed-ended dna molecules |
| US12509711B1 (en) * | 2024-08-09 | 2025-12-30 | Martin Williams | System and process for in vivo manufacturing nanostructure-ended double-stranded covalently-closed linear DNA, the resulting molecules and their uses |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2596303C (en) * | 1997-03-21 | 2013-09-24 | Enzo Therapeutics, Inc. | Vectors and viral vectors and packaging cell lines for propagating same |
| WO2001032899A1 (en) | 1999-10-29 | 2001-05-10 | Takara Shuzo Co., Ltd. | Gene transfer method |
| CN103849629B (zh) * | 2006-06-21 | 2017-06-09 | 尤尼克尔Ip股份有限公司 | 具有经修饰的用于在昆虫细胞中产生aav的aav‑rep78翻译起始密码子的载体 |
| EP2545165B1 (en) * | 2010-03-11 | 2020-07-29 | uniQure IP B.V. | Mutated rep encoding sequences for use in aav production |
| EP2500434A1 (en) * | 2011-03-12 | 2012-09-19 | Association Institut de Myologie | Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery |
| CA2942289C (en) * | 2014-03-10 | 2024-05-21 | Uniqure Ip B.V. | Further improved aav vectors produced in insect cells |
| MX2018010633A (es) * | 2016-03-03 | 2019-06-13 | Univ Massachusetts | Acido desoxirribonucleico (adn) lineal duplex de extremos cerrados para transferencia genica no viral. |
| NZ762100A (en) * | 2017-08-09 | 2025-12-19 | Bioverativ Therapeutics Inc | Nucleic acid molecules and uses thereof |
-
2020
- 2020-02-14 CN CN202080014548.5A patent/CN113454232B/zh active Active
- 2020-02-14 MA MA054958A patent/MA54958A/fr unknown
- 2020-02-14 CA CA3129321A patent/CA3129321A1/en active Pending
- 2020-02-14 SG SG11202106491VA patent/SG11202106491VA/en unknown
- 2020-02-14 US US17/430,341 patent/US20220127625A1/en active Pending
- 2020-02-14 EP EP20756257.0A patent/EP3924491A4/en active Pending
- 2020-02-14 KR KR1020217025576A patent/KR20210127935A/ko active Pending
- 2020-02-14 AU AU2020221312A patent/AU2020221312A1/en active Pending
- 2020-02-14 WO PCT/US2020/018332 patent/WO2020168222A1/en not_active Ceased
- 2020-02-14 JP JP2021547189A patent/JP7644014B2/ja active Active
-
2021
- 2021-08-05 IL IL285415A patent/IL285415A/en unknown
-
2024
- 2024-04-12 JP JP2024064717A patent/JP2024083567A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN113454232A (zh) | 2021-09-28 |
| EP3924491A4 (en) | 2022-12-14 |
| EP3924491A1 (en) | 2021-12-22 |
| CN113454232B (zh) | 2024-10-29 |
| JP2024083567A (ja) | 2024-06-21 |
| IL285415A (en) | 2021-09-30 |
| US20220127625A1 (en) | 2022-04-28 |
| WO2020168222A1 (en) | 2020-08-20 |
| AU2020221312A1 (en) | 2021-10-07 |
| JP2022520803A (ja) | 2022-04-01 |
| KR20210127935A (ko) | 2021-10-25 |
| CA3129321A1 (en) | 2020-08-20 |
| JP7644014B2 (ja) | 2025-03-11 |
| SG11202106491VA (en) | 2021-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA54958A (fr) | Modulation de l'activité de la protéine rep dans la production d'adn à extrémité fermée | |
| MA51113A (fr) | Édition de gène à l'aide d'un adn modifié à extrémités fermées (adnce) | |
| EP3717505A4 (en) | GENENICALLY MODIFIED DNA-BINDING PROTEINS | |
| MA51842A (fr) | Vecteurs d'adn non viraux et utilisations associées pour la production d'anticorps et de protéines de fusion | |
| EP3821011A4 (en) | TRANSPOSOME-ACTIVATED DNA/RNA SEQUENCING (TED RNA-SEQ) | |
| EP3548632A4 (en) | ANALYSIS OF CELL-FREE DNA IN URINE AND OTHER SAMPLES | |
| EP3891157A4 (en) | 4-AMINO- OR 4-ALKOXY-SUBSTITUTED ARYLSULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATE SODIUM CHANNELS | |
| HUE062774T2 (hu) | Módosított rAAV kapszidfehérje génterápiához | |
| EP3964531A4 (en) | PROTEIN MOLECULE AND ITS USE | |
| MA50534A (fr) | Variant d'anticorps et isoforme à activité biologique réduite | |
| MA50159A (fr) | Nouvelles combinaisons stables de charpentes de domaines variables d'anticorps | |
| EP1909831A4 (en) | SELF-BUFFING PROTEIN FORMULATIONS | |
| IS8282A (is) | Kortlagning genamengja starfrænna DNA þátta og frumuprótína | |
| EP2279250A4 (en) | Fusion Molecules of DNA Binding Proteins with Rational Design and Effects Domain | |
| EP3411056A4 (en) | COMPOUNDS FOR NETWORKING DNA BINDING DOMAINS AND SPLITTING DOMAINS | |
| EP3839070A4 (en) | MARKER RELATED TO DNA METHYLATION FOR THE DIAGNOSIS OF TUMORS AND USE THEREOF | |
| EP4058572A4 (en) | HIGH RESOLUTION SPATIAL AND QUANTITATIVE DNA ASSESSMENT | |
| DE602006015164D1 (de) | Kosmetische Verwendung von Molkeproteinmizellen | |
| EP3858866A4 (en) | GLP1-FC FUSION PROTEIN AND ASSOCIATED CONJUGATE | |
| EP4442698A4 (en) | MODIFIED AAV CAPSID PROTEIN AND ITS USE | |
| EP4087940A4 (en) | CELL-FREE DNA MONITORING | |
| IL311656A (en) | Increased yield of milk protein per acre | |
| EP3337497A4 (en) | COMPOSITION AND METHOD FOR THE USE OF NOVEL SMALL ORGANIC PHENYLALANIN COMPOUNDS FOR DIRECT MODULATION OF PCSK9 PROTEIN ACTIVITY | |
| EP4413043A4 (en) | Single-domain anti-BCMA antibodies and therapeutic constructs | |
| EP3787786A4 (en) | MAXIMUM OLEFIN PRODUCTION WITH MULTI-STAGE CATALYST REACTION AND REGENERATION |